Vanda Pharmaceuticals secured FDA approval for Nereus (tradipitant) as the first oral therapy specifically indicated to prevent motion-induced vomiting. The decision follows a comprehensive clinical program involving over 400 participants across three pivotal studies, where Nereus demonstrated a 60% reduction in vomiting episodes compared with placebo (p<0.001). The approval not only validates Vanda’s NK-1 receptor antagonist platform but also establishes Nereus as a potential adjunctive treatment for nausea associated with GLP-1 receptor agonist therapies, opening a new addressable market estimated at $1.2 billion annually in the U.S.

In the third quarter, Vanda reported a 27% year-over-year increase in Fanapt (iloperidone) net product revenue, driven by expanded clinical use in inpatient psychiatric settings and a 15% rise in prescription volume. However, the company recorded a net loss of $22.6 million due to a 45% increase in R&D expenses, reflecting late-stage development costs for Bysanti rheumatoid arthritis candidate, and a 30% uptick in SG&A to support prelaunch activities for Nereus. Management emphasizes these expenses as deliberate investments to bolster the commercial infrastructure ahead of multiple anticipated product launches.

As of September 30, Vanda held $293.8 million in cash, cash equivalents and marketable securities, providing a runway through peak launch periods. The company reiterated its full-year 2025 revenue guidance of $210–230 million, underscoring confidence in continued Fanapt momentum and the upcoming Nereus launch. With Bysanti’s PDUFA target date set for the second quarter of 2026, Vanda expects positive regulatory decisions to drive additional revenue streams and further leverage its existing commercial organization.

Looking into 2026, Vanda highlights two major catalysts: the anticipated U.S. launch of Nereus in mid-year and the PDUFA action date for Bysanti in rheumatoid arthritis. Analyst consensus models project combined peak global sales exceeding $500 million for these assets. Given the company’s current enterprise value multiple of 4.5x next-year revenue, management and analysts believe there is substantial upside potential, particularly if Bysanti secures approval and if Nereus successfully penetrates both the motion sickness and GLP-1–induced nausea markets.